G Bjarnason
Overview
Explore the profile of G Bjarnason including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, et al.
Curr Oncol
. 2019 Jan;
25(6):e576-e584.
PMID: 30607126
Introduction: Outside of randomized controlled clinical trials, the understanding of the effectiveness and costs associated with targeted therapies for metastatic renal cell carcinoma (mrcc) is limited in Canada. The purpose...
2.
Jonker D, Karapetis C, Harbison C, OCallaghan C, Tu D, Simes R, et al.
Br J Cancer
. 2013 Dec;
110(3):648-55.
PMID: 24335920
Background: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit. Methods: Tumour...
3.
Larochelle P, Kollmannsberger C, Feldman R, Schiffrin E, Poirier L, Patenaude F, et al.
Curr Oncol
. 2012 Aug;
19(4):202-8.
PMID: 22876146
Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects...
4.
Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, et al.
Can Urol Assoc J
. 2012 Mar;
6(1):16-22.
PMID: 22396361
No abstract available.
5.
MacKenzie M, Rini B, Elson P, Schwandt A, Wood L, Trinkhaus M, et al.
Ann Oncol
. 2010 Jul;
22(1):145-148.
PMID: 20595449
Background: Temsirolimus is an i.v. administered inhibitor of mammalian target of rapamycin with activity in the first-line setting in poor-prognosis patients with metastatic renal cell carcinoma (RCC). The efficacy of...
6.
Einarsson I, Gudbjartsson T, Einarsson G, Johannsson J, Jonmundsson G, Bjarnason G
Laeknabladid
. 2009 Aug;
84(2):118-24.
PMID: 19667449
Objective: Wilms' tumor is a malignant disease in the kidneys that usually affects young children. Information about the clinical behaviour of this tumor in Iceland has been scarce. The aim...
7.
Freysdottir D, Johannsson J, Bjarnason G
Laeknabladid
. 2009 May;
85(5):408-13.
PMID: 19439802
Introduction: Gastroschisis, a congenital abdominal wall defect, is a rare disorder. The incidence of gastroschisis in Iceland is neither known nor is the results of surgery. Objective: To determine the...
8.
Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G
Can Urol Assoc J
. 2008 Jun;
1(2 Suppl):S41-54.
PMID: 18542784
Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated high activity in renal cell carcinoma (RCC) and is now widely used for patients with metastatic disease. Although generally...
9.
Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C, et al.
Curr Oncol
. 2007 Jun;
13(2):67-76.
PMID: 17576444
Carcinoid tumours are relatively rare and, in general, slow growing. They can be "non-functioning" tumours, presenting as a tumour mass, or "functioning" tumours secondary to the production of several biopeptides...
10.
Gudmundsdottir E, Bjarnason G, Magnusson J
Laeknabladid
. 2006 Oct;
87(12):987-9.
PMID: 17019022
Introduction: Hirschprung s disease (HD) is a congenital disease characterized by the absence of myenteric and submucosal ganglion cells in the distal alimentary tract and results in decreased motility in...